Terms: = Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Prognosis
1166 results:
1. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
[TBL] [Abstract] [Full Text] [Related]
2. [Survival and prognosis of Patients with Acute Myeloid leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome].
Shang LM; Chen HJ; Liu Y; Cao Y; Li F; Guo YT; Dong WM; Lin Y; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):347-354. PubMed ID: 38660835
[TBL] [Abstract] [Full Text] [Related]
3. Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options.
Ma J; Wang Y
Ann Med; 2024 Dec; 56(1):2329132. PubMed ID: 38608646
[TBL] [Abstract] [Full Text] [Related]
4. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
5. Aging and comprehensive molecular profiling in acute myeloid leukemia.
Li JF; Cheng WY; Lin XJ; Wen LJ; Wang K; Zhu YM; Zhu HM; Chen XJ; Zhang YL; Yin W; Zhang JN; Yi X; Zhang F; Weng XQ; Wang SY; Jiang L; Wu HY; Ren JQ; Lin XJ; Qiao N; Dai YT; Fang H; Tan Y; Sun XJ; Lv G; Yan XY; Chen SN; Chen Z; Jin J; Wu DP; Ren RB; Chen SJ; Shen Y
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2319366121. PubMed ID: 38422020
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Relevance of Differential
Kalitin N; Dudina G; Kostritsa N; Sivirinova A; Vaiman A; Karamysheva A
In Vivo; 2024; 38(2):657-664. PubMed ID: 38418133
[TBL] [Abstract] [Full Text] [Related]
7. TP53 in mds and AML: Biological and clinical advances.
Zhao Y; Chen W; Yu J; Pei S; Zhang Q; Shi J; Huang H; Zhao Y
Cancer Lett; 2024 Apr; 588():216767. PubMed ID: 38417666
[TBL] [Abstract] [Full Text] [Related]
8. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
[TBL] [Abstract] [Full Text] [Related]
9. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract] [Full Text] [Related]
10. The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.
Xu F; Jin J; Guo J; Xu F; Chen J; Liu Q; Song L; Zhang Z; Zhou L; Su J; Xiao C; Zhang Y; Yan M; He Q; Wu D; Chang C; Li X; Wu L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):71. PubMed ID: 38305890
[TBL] [Abstract] [Full Text] [Related]
11. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract] [Full Text] [Related]
12. Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.
Kaisrlikova M; Kundrat D; Koralkova P; Trsova I; Lenertova Z; Votavova H; Merkerova MD; Krejcik Z; Vesela J; Vostry M; Simeckova R; Markova MS; Lauermannova M; Jonasova A; Cermak J; Divoky V; Belickova M
Int J Cancer; 2024 May; 154(9):1652-1668. PubMed ID: 38180088
[TBL] [Abstract] [Full Text] [Related]
13. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
[TBL] [Abstract] [Full Text] [Related]
14. When to use which molecular prognostic scoring system in the management of patients with mds?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract] [Full Text] [Related]
15. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract] [Full Text] [Related]
16. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract] [Full Text] [Related]
17. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract] [Full Text] [Related]
18. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
20. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP; Shallis RM; Sharon E; Park S; Ramaswamy R; Roe CE; Irish JM; Caldwell A; Wei W; Yacoub A; Madanat YF; Zeidner JF; Altman JK; Odenike O; Yerrabothala S; Kovacsovics T; Podoltsev NA; Halene S; Little RF; Piekarz R; Gore SD; Kim TK; Zeidan AM
Ann Hematol; 2024 Jan; 103(1):105-116. PubMed ID: 38036712
[TBL] [Abstract] [Full Text] [Related]
[Next]